1-(2-chloroethyl)-5-fluoroisatin | 192928-41-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-(2-chloroethyl)-5-fluoroisatin
• 英文别名: 1-(2-chloroethyl)-5-fluoro-1H-indole-2,3-dione；1-(2-chloroethyl)-5-fluoroindole-2,3-dione
• CAS: 192928-41-9
• 化学式: C₁₀H₇ClFNO₂
• 分子量: 227.622
• InChiKey: LLCXMPZXXDNQCL-UHFFFAOYSA-N

物化性质

• 沸点：
  367.3±52.0 °C(Predicted)
• 密度：
  1.461±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(2-chloroethyl)-5-fluoroisatin 在 palladium on activated charcoal 氢气 、 三乙胺 作用下， 以 1,4-二氧六环 、 乙醇 为溶剂， 生成 [1-(2-Chloro-ethyl)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-yl]-cyano-acetic acid
  参考文献：
  名称：

  Novel, Highly Potent Aldose Reductase Inhibitors:  Cyano(2-oxo-2,3-dihydroindol-3-yl)acetic Acid Derivatives

  摘要：

  Cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives were synthesized and tested as a novel class of aldose reductase (ALR2) inhibitors. Each compound was evaluated as a diastereomeric mixture, due to tautomeric equilibria in solution. The parent compound 39 exhibited a good inhibitory activity with an IC50 value of 0.85 muM, similar to that of the well-known ARI sorbinil (IC50 0.50 muM). The concurrent introduction of a halogen and a lipophilic group in the 5- and in the 1-positions, respectively, of the indole nucleus of 39, gave compound 55, cyano[5-fluoro-1-(4-methylbenzyl)-2-oxo-2,3-dihydroindol-3-yl] acetic acid, which displayed the highest activity (IC50 0.075 muM, very close to that of tolrestat IC50 0.046 muM), with a good selectivity toward ALR2 compared with aldehyde reductase (ALR1) (16.4-fold), and no appreciable inhibitory properties against sorbitol dehydrogenase (SD), or glutathione reductase (GR). The isopropyl ester 59, a prodrug of 55, was found to be almost as effective as tolrestat in preventing cataract development in severely galactosemic rats when administered as an eye drop solution. Docking simulation of 55 into a three-dimensional model of human ALR2 made it possible to formulate the hypothesis that the 2-hydroxy tautomer was the active species binding into the catalytic site of the enzyme. This was fully consistent with the structure-activity relationships within this series of cyanooxoindolylacetic acid derivatives.

  DOI：

  10.1021/jm030762f
• 作为产物：
  描述：

  5-氟靛红 、 1-溴-2-氯乙烷 以 N-甲基乙酰胺 、 mineral oil 为溶剂， 生成 1-(2-chloroethyl)-5-fluoroisatin
  参考文献：
  名称：

  Pharmaceutical compounds

  摘要：

  该药物化合物的化学式为##STR1##及其盐和酯。

  公开号：

  US05773448A1

文献信息

• 5HT1Dalpha and 5HT2A ligands
  申请人：LILLY INDUSTRIES LIMITED

  公开号：EP0780388A1

  公开（公告）日：1997-06-25

  A pharmaceutical compound of the formula in which R1 and R2 are each hydrogen, C1-4 alkyl, C1-4 alkoxy, HO-C1-4 alkyl, C1-4 alkoxy-C1-4 alkyl, C1-4 alkylthio, halo or phCR'R"- where Ph is optionally substituted phenyl and R' and R" are each hydrogen or C1-4 alkyl, or R1 and R2 together with the carbon atom to which they are attached form a C3-6 cycloalkyl group, R3, R4 and R5 are each hydrogen, halo, nitro, C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkyl-CO-, C1-4 alkyl-S(O)m-where m is 0, 1 or 2, R'R"N-SO2-, -COOR', -CONR'R", -NR'R", -N(OR')COOR", -COR', -NHSO2R', where R' and R" are each hydrogen or C1-4 alkyl, R6 and R7 are each hydrogen or C1-4 alkyl, and n is 1 to 6, X is oxygen or sulphur, W is where p is 4 to 7, and q and r are each 1 to 3, Y is 〉CO or -CH(OH)-, and Z is optionally substituted phenyl or optionally substituted heteroaryl; and salts and esters thereof.

  一种药物化合物，其化学式为 其中 R1和R2各自为氢、C1-4烷基、C1-4烷氧基、HO-C1-4烷基、C1-4烷氧基-C1-4烷基、C1-4烷硫基、卤代或phCR'R"- 其中Ph为任选取代的苯基，R'和R "各自为氢或C1-4烷基，或R1和R2与其所连接的碳原子一起形成C3-6环烷基、 R3、R4 和 R5 各自为氢、卤代、硝基、C1-4 烷基、C1-4 烷氧基、C1-4 烷硫基、C1-4 烷基-CO-、C1-4 烷基-S(O)m-（其中 m 为 0、1 或 2）、R'R "N-SO2-、-COOR'、-CONR'R"、-NR'R"、-N(OR')COOR"、-COR'、-NHSO2R'，其中 R' 和 R "各自为氢或 C1-4 烷基、 R6 和 R7 分别为氢或 C1-4 烷基，n 为 1 至 6、 X 是氧或硫、 W 是 其中 p 为 4 至 7，q 和 r 各为 1 至 3、 Y 是 〉CO 或 -CH(OH)-、 和 Z 是任选取代的苯基或任选取代的杂芳基； 及其盐类和酯类。
• Indol-2-ones as serotonin modulators
  申请人：ELI LILLY AND COMPANY LIMITED

  公开号：EP0963983A1

  公开（公告）日：1999-12-15

  Pharmaceutical compounds of the formula: in which n is 1 to 6, m is 1 or 2 and p is 1 or 2, R1 and R2 are each hydrogen, C1-4 alkyl, C1-4 alkoxy, HO-C1-4 alkyl, C1-4 alkoxy-C1-4 alkyl, C1-4 alkylthio, halo, optionally substituted phenyl, optionally substituted phenyl-C1-4 alkyl, or R1 and R2 together with the carbon atom to which they are attached form a C3-6 cycloalkyl group, >C=O, C=NOR' where R' is hydrogen or C1-4 alkyl, R3, R4 and R5 are each hydrogen, halo, nitro, C1-4 alkyl, C1-4 alkoxy, C1-4 alkyl-CO-, where m is 0, 1 or 2, R'R"N-SO2-, -COOR', -CONR'R", -NR'R'', -N(OR')COOR'', -COR', -NHSO2R', where R' and R" are each hydrogen or C1-4 alkyl, R6 and R7 are each hydrogen or C1-4 alkyl, X is oxygen or sulphur, the dotted line represents an optional double bond, and the fluorine atom is attached at the 6- or 7-position; and salts thereof. Compounds (I) are active at the serotonin, 5-HT2A receptor.

  式的药物化合物： 其中 n 为 1 至 6，m 为 1 或 2，p 为 1 或 2、 R1和R2各自为氢、C1-4烷基、C1-4烷氧基、HO-C1-4烷基、C1-4烷氧基-C1-4烷基、C1-4烷硫基、卤代、任选取代的苯基、任选取代的苯基-C1-4烷基，或R1和R2与它们所连接的碳原子一起形成C3-6环烷基，>C=O，C=NOR'，其中R'为氢或C1-4烷基、 R3、R4 和 R5 各自为氢、卤素、硝基、C1-4 烷基、C1-4 烷氧基、C1-4 烷基-CO-（其中 m 为 0、1 或 2）、R'R "N-SO2-、-COOR'、-CONR'R"、-NR'R''、-N(OR')COOR''、-COR'、-NHSO2R'，其中 R' 和 R "各自为氢或 C1-4 烷基、 R6 和 R7 分别为氢或 C1-4 烷基、 X 是氧或硫、 虚线代表任选双键，氟原子连接在 6 位或 7 位；及其盐类。 化合物（I）对 5-羟色胺、5-HT2A 受体具有活性。
• US06166040
  申请人：——

  公开号：——

  公开（公告）日：——
• US5773448A
  申请人：——

  公开号：US5773448A

  公开（公告）日：1998-06-30
• US6166040A
  申请人：——

  公开号：US6166040A

  公开（公告）日：2000-12-26